{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:42Z","timestamp":1792425702871,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Objectives<\/jats:title>\n To describe the clinical predictors and immune-related factors for exacerbation in adults with well-controlled generalized myasthenia gravis (GMG).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a retrospective analysis of 585 adults with well-controlled GMG from our institution to explore the risk factors for exacerbation. Furthermore, propensity score matching (PSM) was used to compare the proportions of lymphocyte subsets, and the levels of immunoglobulin, complement, and anti-acetylcholine receptor antibody (AChR-ab) in the peripheral blood of 111 patients with exacerbations and 72 patients without exacerbations.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 404 patients (69.1%) experienced at least one exacerbation, and the median (interquartile range) time to the first exacerbation was 1.5 years (0.8\u20133.1 years). Multivariable Cox regression analysis showed that age at onset, disease duration before enrollment, Myasthenia Gravis Foundation of America classification (MGFA) class III vs. class II, MGFA class IV-V vs. class II, AChR-ab levels, anti-muscle specific kinase antibody levels, thymus hyperplasia, prednisone plus immunosuppressants vs. prednisone treatment, and thymectomy were independent predictors for exacerbations [hazard ratio (HR) = 1.011, 1.031, 1.580, 1.429, 2.007, 2.033, 1.461, 0.798, and 0.651, respectively]. Propensity-matched analysis compared 51 patient pairs. After PSM, the peripheral blood proportions of CD3\n \u2013<\/jats:sup>\n CD19\n +<\/jats:sup>\n B cells, ratios of CD3\n +<\/jats:sup>\n CD4\n +<\/jats:sup>\n \/CD3\n +<\/jats:sup>\n CD8\n +<\/jats:sup>\n T cells, and AChR-ab levels were significantly increased, and the peripheral blood proportions of CD3\n +<\/jats:sup>\n CD8\n +<\/jats:sup>\n T and CD4\n +<\/jats:sup>\n CD25\n +<\/jats:sup>\n CD127\n low+<\/jats:sup>\n regulatory T cells (Tregs) were significantly lower in patients with exacerbation than in those without exacerbation (all\n p<\/jats:italic>\n &lt; 0.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Myasthenia gravis (MG) exacerbations were more frequent in those patients with older onset age, longer disease duration, more severe MGFA classification, positive AChR-ab, and lack of combined immunotherapy or thymectomy treatment. On the other hand, CD3\n \u2013<\/jats:sup>\n CD19\n +<\/jats:sup>\n B cells, CD3\n +<\/jats:sup>\n CD8\n +<\/jats:sup>\n T cells, Tregs, and AChR-ab in peripheral blood may be involved in the course of GMG exacerbation.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1177249","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:44:19Z","timestamp":1684287859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhuajin","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengcui","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03017.x","article-title":"Course and prognosis of myasthenia gravis: a systematic review","volume":"17","author":"Mao","year":"2010","journal-title":"Eur J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.03.018","article-title":"Prognostic factors for exacerbations and emergency treatments in myasthenia gravis","volume":"282","author":"de Meel","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106130","article-title":"Comparison of peripheral blood b cell subset ratios and b cell-related cytokine levels between ocular and generalized myasthenia gravis","volume":"80","author":"Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221122538","article-title":"Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort","volume":"13","author":"Bi","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050142","article-title":"Prognosis of myasthenia gravis: a retrospective study of 380 patients","volume":"244","author":"Cosi","year":"1997","journal-title":"J Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0303-8467(02)00104-x","article-title":"Relapse of ocular symptoms after remission of myasthenia gravis\u2013a comparison of relapsed and complete remission cases","volume":"105","author":"Wakata","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.816243","article-title":"Clinical predictors of relapse in a cohort of steroid-treated patients with well-controlled myasthenia gravis","volume":"13","author":"Su","year":"2022","journal-title":"Front Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e10248","DOI":"10.7759\/cureus.10248","article-title":"Myasthenia gravis and its association with thyroid diseases","volume":"12","author":"Amin","year":"2020","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.349","article-title":"Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis","volume":"184","author":"Zhang","year":"1996","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1196\/annals.1254.032","article-title":"T Cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"998","author":"Milani","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)44:4<884::AID-ANR145>3.0.CO;2-4","article-title":"A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases","volume":"44","author":"Shibatomi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03424.x","article-title":"Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis","volume":"18","author":"Chien","year":"2011","journal-title":"Eur J Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"Aguirre","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.003","article-title":"Complement associated pathogenic mechanisms in myasthenia gravis","volume":"12","author":"T\u00fcz\u00fcn","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption","volume":"158","author":"Romi","year":"2005","journal-title":"vivo. J Neuroimmunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1177249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:44:23Z","timestamp":1684287863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1177249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2023.1177249"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1177249","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"article-number":"1177249"}}